Enzalutamide in the Context of Nonmetastatic CRPC

Enzalutamide in the non-metastatic setting for CRPC

Abiraterone With or Without Enzalutamide Plus ADT for Non-Metastatic Prostate Cancer

Nonmetastatic CRPC: Considerations for Apalutamide

Safety outcomes of darolutamide vs apalutamide and enzalutamide in nmCRPC

Dr. Gomella on the FDA Approval of Enzalutamide in Nonmetastatic CRPC

SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC?

Live long and PROSPER: enzalutamide for nmCRPC

An Update on the PROSPER Trial: Focusing on Nonmetastatic CRPC

PROSPER: Enzalutamide vs. placebo for nmCRPC

ENZAMET: Enzalutamide for metastatic prostate cancer

Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer.

Considerations for Apalutamide Versus Enzalutamide in Prostate Cancer Treatment

Advances in non-metastatic castration-resistant prostate cancer

TERRAIN: Enzalutamide versus bicalutamide for metastatic prostate cancer

Awaiting key results for enzalutamide and apalutamide in nmCRPC

Enzalutamide in Men with Nonmetastatic, Castration resistant Prostate Cancer.

Understanding non metastatic castration resistant prostate cancer with Dr. Hamilton

The Future of Treatment for Nonmetastatic CRPC

ADT Resistant Non-Metastatic Prostate Cancer (nmCRPC) - 2021 Prostate Cancer Patient Conference